(Q34720452)

4 August 2017

1 reference

title

Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis (English)

1 reference

relapsing-remitting multiple sclerosis

4 August 2017

0 references

0 references

author name string

Omar Khan

1

1 reference

4 August 2017

Rana Zabad

2

1 reference

4 August 2017

Christina Caon

3

1 reference

4 August 2017

Marina Zvartau-Hind

4

1 reference

4 August 2017

Alexandros Tselis

5

1 reference

4 August 2017

Robert Lisak

6

1 reference

4 August 2017

publication date

1 January 2002

1 reference

4 August 2017

1 reference

4 August 2017

volume

16

1 reference

4 August 2017

issue

8

1 reference

4 August 2017

page(s)

563-578

1 reference

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadi

4 August 2017

cites work

1 reference

12 December 2020

Multiple sclerosis: possible immunological mechanisms

1 reference

12 December 2020

Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".

1 reference

12 December 2020

Lack of evidence for involvement of known human retroviruses in multiple sclerosis

1 reference

12 December 2020

Role of viruses in etiology and pathogenesis of multiple sclerosis

1 reference

12 December 2020

Immunology of multiple sclerosis

1 reference

12 December 2020

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

1 reference

12 December 2020

Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide

1 reference

12 December 2020

Multiple sclerosis: trial of a synthetic polypeptide

1 reference

12 December 2020

Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS.

1 reference

12 December 2020

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

Disability indices, the economic costs of illness, and social insurance: the case of multiple sclerosis

1 reference

12 December 2020

Interferons in the treatment of multiple sclerosis: do they prevent the progression of the disease?

1 reference

12 December 2020

MS epidemiology world wide. One view of current status

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Virus interference. I. The interferon

1 reference

12 December 2020

Suppression of experimental allergic encephalomyelitis by COP1--relevance to multiple sclerosis

1 reference

12 December 2020

Randomized, controlled trials, observational studies, and the hierarchy of research designs

1 reference

12 December 2020

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

12 December 2020

The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis

1 reference

12 December 2020

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

1 reference

12 December 2020

A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Intrathecal Interferon Reduces Exacerbations of Multiple Sclerosis

1 reference

12 December 2020

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group

1 reference

12 December 2020

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

1 reference

12 December 2020

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

1 reference

12 December 2020

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

1 reference

12 December 2020

Immunomodulatory effects of interferon beta-1a in multiple sclerosis

1 reference

12 December 2020

Intrathecally administered natural human fibroblast interferon reduces exacerbations of multiple sclerosis. Results of a multicenter, double-blind study

1 reference

12 December 2020

Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system

1 reference

12 December 2020

Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-beta

1 reference

12 December 2020

A comparison of observational studies and randomized, controlled trials

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1

1 reference

12 December 2020

Immunological aspects of demyelinating diseases

1 reference

12 December 2020

Why we need observational studies to evaluate the effectiveness of health care

1 reference

12 December 2020

"Summary measure" statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Induction of a non-encephalitogenic type 2 T helper-cell autoimmune responsein multiple sclerosis after administration of an altered peptide ligand ina placebo-controlled, randomized phase II trial

1 reference

12 December 2020

The interferons: biological effects, mechanisms of action, and use in multiple sclerosis

1 reference

12 December 2020

Mechanisms of immunomodulation by glatiramer acetate

1 reference

12 December 2020

Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis.

1 reference

12 December 2020

TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability

1 reference

12 December 2020

Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators

1 reference

12 December 2020

Mechanisms of action of glatiramer acetate in multiple sclerosis

1 reference

12 December 2020

Interferon beta induces T-helper 2 immune deviation in MS

1 reference

12 December 2020

A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis

1 reference

12 December 2020

Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA.

1 reference

12 December 2020

Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up

1 reference

12 December 2020

Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group

1 reference

12 December 2020

T cells in multiple sclerosis and inflammatory central nervous system diseases

1 reference

12 December 2020

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

12 December 2020

Depletion of myelin-basic-protein autoreactive T cells by T-cell vaccination: pilot trial in multiple sclerosis

1 reference

12 December 2020

Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9.

1 reference

12 December 2020

Interferon beta in the treatment of multiple sclerosis: mechanisms of action

1 reference

12 December 2020

T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies

1 reference

12 December 2020

Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and AVONEX.

1 reference

12 December 2020

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

12 December 2020

Electron microscopy and immunoperoxidase studies of early multiple sclerosis lesions

1 reference

12 December 2020

Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis

1 reference

12 December 2020

Axonal transection in the lesions of multiple sclerosis

1 reference

12 December 2020

The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation

1 reference

12 December 2020

A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy

1 reference

12 December 2020

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

12 December 2020

A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions

1 reference

12 December 2020

Immunology of multiple sclerosis

1 reference

12 December 2020

How well is the clinical importance of study results reported? An assessment of randomized controlled trials

1 reference

12 December 2020

Human and murine CD4 T cell reactivity to a complex antigen: recognition of the synthetic random polypeptide glatiramer acetate

1 reference

12 December 2020

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

10.2165/00023210-200216080-00005

Identifiers

DOI

1 reference

Dimensions Publication ID

4 August 2017

1025237987

0 references

1 reference